Avelumab, a PD-L1 Inhibitor, in Combination with Hypofractionated Radiotherapy and the Abscopal Effect in Relapsed Refractory Multiple Myeloma

Dickran Kazandjian*, Alexander Dew, Elizabeth Hill, Elizabeth Gil Ramirez, Candis Morrison, Esther Mena, Liza Lindenberg, Constance Yuan, Irina Maric, Hao Wei Wang, Katherine Calvo, Alina Dulau-Florea, Joseph Roswarski, Michael Emanuel, Raul Braylan, Baris Turkbey, Peter Choyke, Kevin Camphausen, Maryalice Stetler-Stevenson, Seth M. SteinbergWilliam D. Figg, Jennifer C. Jones

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

10 Scopus citations

Fingerprint

Dive into the research topics of 'Avelumab, a PD-L1 Inhibitor, in Combination with Hypofractionated Radiotherapy and the Abscopal Effect in Relapsed Refractory Multiple Myeloma'. Together they form a unique fingerprint.

Medicine & Life Sciences